Phase II Study of Hypofractionated Radiation Therapy to Augment Immune Response in Patients With Metastatic Gastrointestinal Malignancies Progressing on Immune Therapy (ARM-GI)
Summary
This phase II trial studies how well radiation therapy works for the treatment of gastrointestinal cancer that are spreading to other places in the body (metastatic). Radiation therapy uses high energy x-rays to kill cancer cells and shrink tumors. This trial is being done to determine if giving radiation therapy to patients who are being treated with immunotherapy and whose cancers are progressing (getting worse) can slow or stop the growth of their cancers. It may also help researchers determine if giving radiation therapy to one tumor can stimulate the immune system to attack other tumors in the body that are not targeted by the radiation therapy.
General Information
NCT#: NCT04221893
Study ID: 19721
Trial Phase: Phase II
Trial Sponsor: University of California, San Francisco (UCSF), Varian, a Siemens Healthineers Company
Therapies Used in This Trial: Hypofractionated radiation therapy
Sign In